Angiotensin-converting enzyme inhibition and vascular remodeling in coronary artery disease

Coronary Artery Disease

Volumn 9, Issue 10, 1998, Pages 675-684

  Adams Jr , Kirkwood F ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Angiotensin converting enzyme inhibitors; Renin angiotensin system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; KININ; RENIN;

ARTERY RECONSTRUCTION; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY SURGERY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION;

EID: 7844235471     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199809100-00007     Document Type: Review

References (105)

1. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340:1173-1178.
2. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994; 330:1431-1438.
3. Francis GS. The role of ACE inhibitors in preventing myocardial infarction: potential mechanisms and clinical implications. Eur Heart J 1995; 16 (suppl K):1-3.
4. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90:2056-2069.
5. Cruzen NP, Fox KM. Do ACE inhibitors modulate atherosclerosis? Eur Heart J 1997; 18:1530-1535.
6. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med 1986; 314:488-499.
7. Cody RJ. The integrated effects of angiotensin II. Am J Cardiol 1997; 79:9-11.
8. Erdos EG. Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol 1990; 15 (suppl 6):S20-S24.
9. Rosendorff C. The renin-angiotensin system and vascular hypertrophy. J Am Coll Cardiol 1996; 28:803-812.
10. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation 1993; 87:1816-1828.
11. Samani NJ, Swales JD. Molecular biology of the vascular renin-angiotensin system. Blood Vessels 1991; 28:210-216.
12. Corvol P, Michaud A, Soubrier F, Williams TA. Recent advances in knowledge of the structure and function of the angiotensin I converting enzyme. J Hypertens 1995; 13 (suppl 3):S3-S10.
13. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation 1994; 89:493-508.
14. Katz AM. Angiotensin II: hemodynamic regulator or growth factor? J Mol Cell Cardiol 1990; 22:739-747.
15. Urata H, Nishimura H, Ganten D. Mechanisms of angiotensin II formation in humans. Eur Heart J 1995; 16 (suppl N):79-85.
16. Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens 1993; 11 (suppl 3):S13-S18.
17. Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept 1993; 43:1-20.
18. Klickstein LB, Kaempfer CE, Wintraub BY. The granulocyte angiotensin system. Angiotensin I-converting activity of cathepsin G. J Biol Chem 1982; 257:15042-15046.
19. Tang SS, Loscalzo J, Dzau VJ. Tissue plasminogen activator activates renin angiotensin in vitro. J Vasc Med Biol 1989; 1:67-74.
20. Barth A, Wahab M, Brandt W, Frost K. Classification of serine proteases derived from steric comparisons of their active sites. Drug Design & Discovery 1993; 10:297-317.
21. Urata J, Nishimura H, Ganten D. Chymase-dependent angiotensin II forming system in humans. Am J Hypertens 1996; 9:277-284.
22. Husain A. The chymase-angiotensin system in humans. J Hypertens 1993; 11:1155-1159.
23. Vago T, Bevilacqua M, Conci F, Baldi G, Ongini E, Chebat E, et al. Angiotensin converting enzyme binding sites in human heart and lung: comparison with rat tissues. Br J Pharmacol 1992; 107:821-825.
24. Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 1997; 80:219-227.
25. Zisman LS, Abraham WT, Meixell GE, Vamvakias BN, Quaife RA, Lowes BD, et al. Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway. J Clin Invest 1995; 96:1490-1498.
26. Hoit BD, Shao Y, Kinoshita A, Gabel M, Husain A, Walsh RA. Effects of angiotensin II generated by an angiotensin converting enzyme-independent pathway on left ventricular performance in the conscious baboon. J Clin Invest 1995; 95:1519-1527.
27. Unger T, Chung O, Csikos T, Culman J, Gallinat S, Gohlke P, et al. Angiotensin receptors. J Hypertens 1996; 14 (suppl 5):S95-S103.
28. Timmermans PBMWM, Smith RD. Angiotensin II receptor subtypes: selective antagonists and functional correlates. Am Heart J 1994; 15 (suppl D):79-87.
29. 2 receptors in the developing rat fetus. J Clin Invest 1991; 88:921-933.
30. 2 angiotensin II receptor subtypes in the rat brain during development. Proc Natl Acad Sci USA 1991; 88:1140-1144.
31. 2 angiotensin II receptors in rat anterior cerebral arteries. Am J Physiol 1991; 261:H667-H670.
32. 2) in rat brain. Am J Physiol 1991; 261:R209-R216.
33. Viswanathan M, Tsutsumi K, Correa FM, Saavedra JM. Changes in expression of angiotensin receptor subtypes in the rat aorta during development. Biochem Biophys Res Commun 1991; 179:1361-1367.
34. Dzau VJ. Vascular renin-angiotensin system and vascular protection. J Cardiovasc Pharmacol 1993; 22 (suppl 5):S1-S9.
35. Kambayashi Y, Bardham S, Inagami T. Peptide growth factors markedly decrease the ligand binding of angiotensin II type 2 receptor in rat cultured vascular smooth muscle cells. Biochem Biophys Res Commun 1993; 194:478-482.
36. 2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95:651-657.
37. 2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest 1996; 98:418-425.
38. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997; 99:1926-1935.
39. 2 receptors are in the spotlight. J Clin Invest 1996; 97:1787-1788.
40. Rogers TB, Lokuta AJ. Angiotensin II signal transduction pathways in the cardiovascular system. Trends Cardiovasc Med 1994; 4:110-116.
41. Komuro I, Yazaki Y. Intracellular signaling pathways in cardiac myocytes induced by mechanical stress. Trends in Cardiovascular Medicine 1994; 4:117-212.
42. Griendling KK, Tsuda T, Berk BC, Alexander RW. Angiotensin II stimulation of vascular smooth muscle cells. Am J Hypertens 1989; 2:659-665.
43. Farago A, Nishizuka Y. Protein kinase C in transmembrane signalling. FEBS Lett 1990; 268:350-354.
44. 2+ mobilization and protein kinase C activation. J Biol Chem 1989; 264:526-530.
45. Molloy CJ, Taylor DS, Weber H. Angiotensin II stimulation of rapid protein tyrosine phosphorylation and protein kinase activation in rat aortic smooth muscle cells. J Biol Chem 1993; 268; 73:8-45.
46. Davis RJ. The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 1993; 268:14553-14566.
47. Schieffer, Paxton WG, Marrero MB, Bernstein KE. Importance of tyrosine phosphorylation in angiotensin II type 1 receptor signaling. Hypertension 1996; 27:476-480.
48. + exchange and intracellular pH. J Biol Chem 1990; 265:19632-19637.
49. Geisterfer AT, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988; 62:749-756.
50. + exchange. J Clin Invest 1989; 83:822-829.
51. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83:1419-1424.
52. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia. J Clin Invest 1992; 90:456-461.
53. Stoffer GA, Owens GK. Angiotensin II induced mitogenesis of spontaneously hypertensive rat derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor-beta. Circ Res 1992; 70:820-887.
54. Ito H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple aulocrine growth factors modulate vascular smooth muscle cells growth response to angiotensin II. J Clin Invest 1993; 91:2268-2274.
55. Wollert KC, Drexler H. The kallikrein-kinin system in post-myocardial infarction cardiac remodeling. Am J Cardiol 1997; 80 (suppl 3A):158A-161A.
56. Holtz J, Goetz RM. Vascular renin-angiotensin system, endothelial function and atherosclerosis? Basic Res Cardiol 1994; 89 (suppl 1):71-86.
57. Dzau VJ. Pathobiology of atherosclerosis and plaque complications. Am Heart J 1994; 128:1300-1304.
58. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327:524-526.
59. Kinsella MG, Wight TN. Modulation of sulfated proteoglycan synthesis by bovine aortic endothelial cells during migration. J Cell Biol 1986; 102:678-687.
60. Udenfriend S, Cardinale G, Spector S. Hypertension induced vascular fibrosis and its reversal by antihypertensive drugs. In: Laragh JH, Buhler FR, Seldin OW (editors): Frontiers in hypertension research. New York: Springer-Verlag; 1981. pp. 404-411.
61. Dohi Y, Hahn AWA, Boulanger CM, Buhler FR, Luscher TF. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension 1992; 19:131-137.
62. Hahn AW, Jonas U, Buhler FR, Resink TJ. Activation of human peripheral monocytes by angiotensin II. FEBS Lett 1994; 347:178-180.
63. Urata H, Hoffmann S, Ganten D. Tissue angiotensin II system in the human heart. Eur Heart J 1994; 15 (suppl D):68-78.
64. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94:2756-2767.
65. Powell JS, Clozel JP, Muller RKM, Kuhn H, Hefti F, Hosang M, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245:186-188.
66. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990; 15:327-331.
67. Rakugi H, Jacob HJ, Krieger JE, Ingelfinger JR, Pratt RE. Vascular injury induces angiotensinogen gene expression in the media and neointima. Circulation 1993; 87:283-290.
68. Schuh JR, Blehm DJ, Frierdich GE, McMahon EG, Blame EH. Differential effects of reninnangiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest 1993; 91:1453-1458.
69. Lam JYT, Bourassa MJ, Blaine L, Lachapelle C. Can cilazapril reduce the development of atherosclerotic changes in the balloon injured porcine carotid arteries? [abstract]. Circulation 1990; 82 (suppl III):III-429.
70. Hanson SR, Powell JS, Dodson T, Lumsden A, Kelly AB, Anderson JS, et al. Effects of angiotensin converting enzyme inhibition with cilazapril on intimal hyperplasia in injured arteries and vascular grafts in the baboon. Hypertension 1991; 18 (suppl II):1170-1176.
71. Chobanian AV. The effects of ACE inhibitors and other antihypertensive drugs on cardiovascular risk factors and atherogenesis. Clin Cardiol 1990; 15:327-331.
72. Chobanian AV, Hope S, Brecher P. Dissociation between the antiatherosclerotic effect of trandolapril and suppression of serum and aortic angiotensin-converting enzyme activity in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990; 15:327-331.
73. Rolland PH, Charpiot P, Friggi A, Piquet P, Barlatier A, Scalbert E, et al. Effects of angiotensin-converting enzyme inhibition with perindolol on hemodynamics, arterial structure, and wall rheology in the hindquarters of atherosclerotic mini-pigs. Am J Cardiol 1993; 71 (suppl E):22E-27E.
74. Epstein SE, Speir E, Unger EF, Guzman RJ, Finkel T. The basis of molecular strategies for treating coronary restenosis after angioplasty. J Am Coll Cardiol 1994; 23:1278-1288.
75. Tsuda T, Alexander RW. Angiotensin II stimulates phosphorylation of nuclear lamins via a protein kinase C-dependent mechanism in cultured vascular smooth muscle cells. J Biol Chem 1990; 265:1165-1170.
76. Koh E, Morimoto S, Tomita J, Rakugi H, Jiang B, Inoue T, et al. Effects of an angiotensin II receptor antagonist, CV-11974, on angiotensin II-nduced increases in cytosolic free calcium concentration, hyperplasia and hypertrophy of cultured vascular smooth muscle cells. J Cardiovasc Pharmacol 1994; 23:175-179.
77. Vanhoutte PM, Boulanger CM, Mombouli JV. Endothelium-derived relaxing factors and converting enzyme inhibition. Am J Cardiol 1995; 76 (suppl 15):3E-12E.
78. Cosentino F, Luscher TF. Maintenance of vascular integrity: role of nitric oxide and other bradykinin mediators. Eur Heart J 1995; 15 (suppl K):4-12.
79. Mombouli JV, Illiano S, Nagao T, Scott-Burden T, Vanhoutte PM. The potentiation of endothelium-dependent relaxations to bradykinin by angiotensin-converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and contracting factors. Circ Res 1992; 71:137-144.
80. Becker RHA, Wiemer G, Linz W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol 1991; 18 (suppl 2):110-115.
81. Vaughan DE, Shen C, Lazos SA. Angiotensin II induces secretion of plasminogen activator inhibitor (PAI-1) in vitro [abstract]. Circulation 1992; 86 (suppl I):I-557.
82. Ridker PM. An epidemiologic assessment of thrombotic risk factors for cardiovascular disease. Curr Opin Lipidol 1992; 3:285-290.
83. 2+ concentrations in essential hypertension. Hypertension 1993; 22:853-862.
84. Moser L, Callahan KS, Cheung AK, Stoddard GJ, Munger MA. ACE inhibitor effects on platelet function in stages I-II hypertension. J Cardiovasc Pharmacol 1997; 30:461-467.
85. Fennessy PA, Campbell JH, Mendelsohn FA, Campbell GR. Angiotensin-converting enzyme inhibitors and atherosclerosis: relevance of animal models to human disease. Clin Exp Pharmacol Physiol 1996; 23:S30-S32.
86. Linz W, Wiemer G, Scholkens BA. Contribution of bradykinin to the cardiovascular effects of ramipril. J Cardiovasc Pharmacol 1993; 22 (suppl 9):S1-S8.
87. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286:441-449.
88. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324:1098-1104.
89. Soubrier F, Nadaud S, Williams TA. Angiotensin I converting enzyme gene: regulation, polymorphism and implications in cardiovascular diseases. Eur Heart J 1994; 15 (suppl D):24-29.
90. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, et al. Deletion polymorphism in the gene for angiotensin converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359:641-644.
91. Sigusch HH, Vogt S, Gruber U, Reinhardt D, Lang K, Surber R, et al. Angiotensin-I-converting enzyme DD genotype is a risk factor of coronary artery disease. Scand J Clin Lab Invest 1997; 57:127-132.
92. Dakik HA, Mahmanan JJ, Verani MS, Farmer JA, Zhao G, Marian AJ. Association of angiotensin I-converting enzyme gene polymorphism with myocardial ischemia and patency of infarct-related artery in patients with acute myocardial infarction. J Am Coll Cardiol 1997; 29:1468-1473.
93. Amant C, Bauters C, Bodart JC, Lablanche JM, Grollier G, Danchin N, et al. D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation 1997; 96:56-60.
94. Foy CA, Rice GI, Ossei-Gerning N, Mansfield MW, Grant PJ. Angiotensin-converting enzyme (ACE) gene ploymorphisms in patients characterized by coronary angiography. Hum Genet 1997; 100:420-425.
95. Ludwig EH, Borecki IB, Ellison RC, Folsom AR, Heiss G, Higgins M, et al. Associations between candidate loci angiotensin-converting enzyme and angiotensinogen with coronary heart disease and myocardial infarction: the NHLBI Family Heart Study. Ann Epidemiol 1997; 7:3-12.
96. Odawara M, Yamashita K. Reliability of angiotensin-converting enzyme gene polymorphism in testing. Ann Intern Med 1997; 126:828.
97. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
98. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685-691.
99. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327:669-677.
100. Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Flaker GC, Kowey PR, et al., on behalf of the SAVE Investigators. Effects of captopril on ischemic events after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. Circulation 1994; 90:1731-1738
101. Repine CJ. Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function. J Am Coll Cardiol 1996; 27:1048-1052.
102. The HOPE Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 1996; 12:127-137.
103. Texter M, Lees RS, Pitt B, Dinsmore RE, Uprichard AC. The QUinapril Ischemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention. Cardiovas Drug Ther 1993; 7:273-282.
104. The Multicenter European Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR randomized, double blind placebo-controlled trial. Circulation 1992; 86:100-110.
105. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94:258-265.